Regulation of plasminogen activator inhibitor activity in endothelial cells by tissue-type plasminogen activator

Fibrinolysis

Volumn 10, Issue 3, 1996, Pages 183-191

  Shi, G Y ^a   Hsu, C C ^a   Chang, B I ^a   Tsai, C F ^a   Han, H S ^a   Lai, M D ^a   Lin, M T ^a   Chang, W C ^a   Wing, L Y C ^a   Jen, C J ^a   Tang, M J ^a   Wu, H L ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; MESSENGER RNA; METHIONINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; STREPTOKINASE; SULFUR 35; UROKINASE;

ACUTE HEART INFARCTION; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBRINOLYTIC THERAPY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; ISOTOPE LABELING; MESSENGER RNA SYNTHESIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; REGULATORY MECHANISM; VASCULAR ENDOTHELIUM;

EID: 0029682180     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(96)80030-0     Document Type: Article

References (55)

1. Jaffe E A, Hoyer L W, Nachman R L. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest 1973; 52: 2757-64.
2. Pearlstein E, Gold L I, Garcia-Pardo A. Fibronectin: a review of its structure and biological activity. Mol Cell Biochem 1980; 29: 103-28.
3. Mosher D F, Doyle M J, Jaffe E A. Synthesis and secretion of thrombospondin by cultured human endothelial cells. J Cell Biol 1982; 93: 343-48.
4. Moncada S, Vane J R. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med 1979; 300: 1142-47.
5. Owen W G, Esmon C T. Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of Protein C. J Biol Chem 1981; 256: 5532-35.
6. Marcum J A, Rosenberg R D, Anticoagulantly active heparin-like molecules from the vascular tissue. Biochemistry 1984; 23: 1730-37.
7. Loskutoff D J, van Mourik J A, Erickson L A, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 1983; 80: 2956-60.
8. Kruithof E K, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-13.
9. Ramakrishnan V, Sinicropi D V, Dere R, Darbonne W C, Bechtol K B, Baker J B. Interaction of wild-type and catalytically inactive mutant forms of tissue-type plasminogen activator with human umbilical vein endothelial cell monolayers. J Biol Chem 1990; 265: 2755-62.
10. Bachman F, Kruithof E K. Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Haemost 1984; 10: 6-17.
11. Levin E G, Loskutoff D J. Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators. J Cell Biol 1982; 94: 631-36.
12. van Mourik J A, Lawrence D A, Loskutoff D J. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 1984; 259: 14914-21.
13. Andreasen P A, Nielsen L S, Kristensen P, Grondahl-Hansen J, Skriver L, Dano K. Plasminogen activator inhibitor from human fibrosarcoma cells binds uorkinase-type plasminogen activator, but not its proenzyme. J Biol Chem 1986; 261: 7644-51.
14. Coleman P L, Barouski P A, Gelehrter T D. The dexamethasone-induced inhibitor of fibrinolytic activity in hepatoma cells. J Biol Chem 1982; 257: 4260-63.
15. Erickson L A, Hekman C M, Loskutoff D J. The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci USA 1985; 82: 8710-14.
16. Levin E G, Santell L. Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells. J Cell Biology 1987; 105: 2543-49.
17. Bartha K, Declerck P J, Moreau H, Nelles L, Collen D. Synthesis and secretion of plasminogen activator inhibitor 1 by human endothelial cells in vitro. J Biol Chem 1991; 266: 792-97.
18. Shi G Y, Hau J S, Wang S J, et al. Plasmin and the regulation of tissue-type plasminogen activator biosynthesis in human endothelial cells. J Biol Chem 1992; 267: 19363-68.
19. Dichek D, Quertermous T. Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Blood 1989; 74: 222-28.
20. Mayer M, Lund L R, Riccio A, et al. Plasminogen activator inhibitor type-1 protein, mRNA and gene transcription are increased by phorbol esters in human rhabdomyosarcoma cells. J Biol Chem 1988; 263: 15688-93.
21. Partridge C A, Gerritsen M E. Dexamethasone increases the release of three 44 kD proteins immunologically related to plasminogen activator inhibitor-1 from human umbilical vein endothelial and rabbit coronary microvessel endothelial cells. Thromb Res 1990; 57: 139-54.
22. Colucci M, Paramo JA, Collen D. Generation in plasma of a fastacting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-24.
23. Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibit of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-66.
24. Topol E J, George B S, Kereiakes D J, et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79: 281-86.
25. Merlini P A, Cattaneo M, Spinola A, et al. Activation of the hemostatic system during thrombolytic therapy. Am J Cardiol 1993; 72: 59G-65G.
26. Califf R M, Fortin D F, Tenaglia A N, Sane D C. Clinical risks of thrombolytic therapy. Am J Cardiol 1992; 69: 12A-20A.
27. Gram J, Jespersen J, Kluft C, Rijken D C. On the usefulness of fibrinolytic variables in the characterization of a risk group for myocardial infarction. Acta Med Scand 1987; 221: 149-53.
28. Bleich S D, Nichols T C, Schumacher R R, Cook D H, Tate D A, Teichman S L. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in myocardial infraction. Am J Cardiol 1990; 66: 1412-17.
29. Verstraete M, Arnold A, Brower R W, et al. Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: Initial patency and influence of maintained infusion on reocclusion rate. Am J Cardiol 1987; 60: 231-37.
30. Gold H K, Leinbach R C, Garabedian H D, et al. Acute coronary reocclusion after thrombolysis with recombinant human tissuetype plasminogen activator: Prevention by a maintenance infusion. Circulation 1986; 73: 347-52.
31. Stump D C, Califf R M, Topol E J, et al. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Circulation 1989; 80: 1222-30.
32. Underbill D M, Owensby D A, Morton P A, Schwartz A L. Endocytosis and lysosomal delivery of tissue plasminogen activator-inhibitor complexes in Hep G2 cells. Blood 1992; 80: 2746-54.
33. Owensby D A, Morton P A, Schwartz A L. Interactions between tissue-type plasminogen activator and extracellular matrix associated plasminogen activator inhibitor type 1 in the human hepatoma cell line Hep G2. J Biol Chem 1989; 264: 18180-87.
34. Owensby D A, Sobel B E, Schwartz A L. Receptor-mediated endocytosis of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. J Biol Chem 1988; 263: 10587-94.
35. Morton P A, Owensby D A, Sobel B E, Schwartz A L. Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. J Biol Chem 1989; 264: 7228-35.
36. Hajjar K A, Hamel N M. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J Biol Chem 1990; 265: 2908-16.
37. Hajjar K A. The endothelial cell tissue plasminogen activator receptor. J Biol Chem 1991; 266: 21962-70.
38. Levin E G, Marzec U, Anderson J, Harker L A. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest 1984; 74: 1988-95.
39. Lowry O H, Rosebrough N J, Farral A L, Randall R J. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75.
40. Van Hinsbergh V W M, Sprengers E D, Kooistra T. Effect of thrombin on the production of plasminogen activators and PA inhibitor-1 by human foreskin micro vascular endothelial cells. Thromb Haemost 1987; 57: 148-53.
41. Verheijen J H, Chang G T G, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost 1984; 51: 392-95.
42. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-59.
43. Levin E G, Marotti K R, Santell L. Protein kinase C and the stimulation of tissue plasminogen activator release from human endothelial cells. J Biol Chem 1989; 264: 16030-36.
44. Bosma P J, Kooistra T. Different induction of two plasminogen activator inhibitor 1 mRNA species by phorbol ester in human hepatoma cells. J Biol Chem 1991; 266: 17845-49.
45. Ginsberg D, Zeheb R, Yang A Y, et al. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 1986; 78: 1673-80.
46. Ye R D, Wun T C, Sadler J E. Mammalian protein secretion without signal peptide removal. J Biol Chem 1988; 263: 4869-75.
47. Laemmli U K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-85.
48. Ny T, Sawdey M, Lawrence D, Millan J L, Loskutoff D J. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83: 6776-80.
49. Hajjar K A, Hamel N M, Harpel P C, Nachman R L. Binding of tissue-plasminogen activator to cultured human endothelial cells. J Clin Invest 1987; 80: 1712-19.
50. Bu G, Warshawsky I, Schwartz A L. Cellular receptors for the plasminogen activators. Blood 1994; 83: 3427-36.
51. Russell M E, Quertermous T, Declerck P J, Collen D, Haber E, Homey C J. Binding of tissue-type plasminogen activator with human endothelial cell monolayers. J Biol Chem 1990; 265: 2569-75.
52. Barnathan E S, Kuo A, Van der Keyl H, McCrae K R, Larsen G R, Cines D B. Tissue-type plasminogen activator binding to human endothelial cells: Evidence for two distinct binding sites. J Biol Chem 1988; 263: 7792-99.
53. Laiho M, Saksela O, Keski-Oja J. Transforming growth factor-β induction of type-1 plasminogen activator inhibitor: Pericellular deposition and sensitivity to exogenous urokinase. J Biol Chem 1987; 262: 17467-74.
54. Grobmyer S R, Kuo A, Orishimo M, Okada S S, Cines D B, Barnathan E S. Determinants of binding and internalization of tissue-type plasminogen activator by human vascular smooth muscle and endothelial cells. J Biol Chem 1993; 268: 13291-300.
55. Garabedian H D, Gold H K, Leinbach R C, Johns J A, Yasuda T, Kanke M, et al. Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. J Am Coll Cardiol 1987; 9: 599-607.